Biodesix Reports Impressive 45% Revenue Growth in 2024

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, has announced preliminary, unaudited results for the fourth quarter and full-year 2024, showcasing remarkable financial momentum. Total revenue reached an estimated $71.3 million for 2024, marking a 45% increase year-over-year, with Q4 revenue at $20.4 million, up 39%. This significant growth is driven by both core segments, with Lung Diagnostics contributing $64.7 million (up 43%) and Biopharma Services exhibiting exceptional growth of 69%.